Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy

Kimberly S. Collins, Victoria M. Pratt, Wesley M. Stansberry, Elizabeth B. Medeiros, Karthik Kannegolla, Marelize Swart, Todd Skaar, Arlene B. Chapman, Brian Decker, Ranjani Moorthi, Michael Eadon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates hypertension. A generalized approach to drug selection and dosage has not proven effective in managing these conditions, in part, because patients with heterogeneous kidney disease and hypertension etiologies are frequently grouped according to functional or severity classifications. Genetic testing may serve as an important tool in the armamentarium of clinicians who embrace precision medicine. Increasing scientific evidence has supported the utilization of genomic information to select efficacious antihypertensive therapy and understand hereditary contributors to chronic kidney disease progression. Given the wide array of antihypertensive agents available and diversity of genetic renal disease predictors, a panel-based approach to genotyping may be an efficient and economic means of establishing an individualized blood pressure response profile for patients with various forms of chronic kidney disease and hypertension. In this manuscript, we discuss the validation process of a Clinical Laboratory Improvement Amendments-approved genetic test to relay information on 72 genetic variants associated with kidney disease progression and hypertension therapy. These genomic-based interventions, in addition to routine clinical data, may help inform physicians to provide personalized therapy.

Original languageEnglish (US)
Pages (from-to)18-22
Number of pages5
JournalPharmacogenetics and Genomics
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Chronic Renal Insufficiency
Antihypertensive Agents
Hypertension
Disease Progression
Kidney Diseases
Therapeutics
Kidney
Precision Medicine
Inborn Genetic Diseases
Genetic Testing
Economics
Blood Pressure
Physicians
Pharmaceutical Preparations

Keywords

  • chronic kidney disease
  • hypertension
  • implementation
  • Pharmacogenomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. / Collins, Kimberly S.; Pratt, Victoria M.; Stansberry, Wesley M.; Medeiros, Elizabeth B.; Kannegolla, Karthik; Swart, Marelize; Skaar, Todd; Chapman, Arlene B.; Decker, Brian; Moorthi, Ranjani; Eadon, Michael.

In: Pharmacogenetics and Genomics, Vol. 29, No. 1, 01.01.2019, p. 18-22.

Research output: Contribution to journalArticle

Collins, Kimberly S. ; Pratt, Victoria M. ; Stansberry, Wesley M. ; Medeiros, Elizabeth B. ; Kannegolla, Karthik ; Swart, Marelize ; Skaar, Todd ; Chapman, Arlene B. ; Decker, Brian ; Moorthi, Ranjani ; Eadon, Michael. / Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. In: Pharmacogenetics and Genomics. 2019 ; Vol. 29, No. 1. pp. 18-22.
@article{3f2abb8a9777423ebb5a8a419b713f15,
title = "Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy",
abstract = "Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates hypertension. A generalized approach to drug selection and dosage has not proven effective in managing these conditions, in part, because patients with heterogeneous kidney disease and hypertension etiologies are frequently grouped according to functional or severity classifications. Genetic testing may serve as an important tool in the armamentarium of clinicians who embrace precision medicine. Increasing scientific evidence has supported the utilization of genomic information to select efficacious antihypertensive therapy and understand hereditary contributors to chronic kidney disease progression. Given the wide array of antihypertensive agents available and diversity of genetic renal disease predictors, a panel-based approach to genotyping may be an efficient and economic means of establishing an individualized blood pressure response profile for patients with various forms of chronic kidney disease and hypertension. In this manuscript, we discuss the validation process of a Clinical Laboratory Improvement Amendments-approved genetic test to relay information on 72 genetic variants associated with kidney disease progression and hypertension therapy. These genomic-based interventions, in addition to routine clinical data, may help inform physicians to provide personalized therapy.",
keywords = "chronic kidney disease, hypertension, implementation, Pharmacogenomics",
author = "Collins, {Kimberly S.} and Pratt, {Victoria M.} and Stansberry, {Wesley M.} and Medeiros, {Elizabeth B.} and Karthik Kannegolla and Marelize Swart and Todd Skaar and Chapman, {Arlene B.} and Brian Decker and Ranjani Moorthi and Michael Eadon",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/FPC.0000000000000361",
language = "English (US)",
volume = "29",
pages = "18--22",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy

AU - Collins, Kimberly S.

AU - Pratt, Victoria M.

AU - Stansberry, Wesley M.

AU - Medeiros, Elizabeth B.

AU - Kannegolla, Karthik

AU - Swart, Marelize

AU - Skaar, Todd

AU - Chapman, Arlene B.

AU - Decker, Brian

AU - Moorthi, Ranjani

AU - Eadon, Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates hypertension. A generalized approach to drug selection and dosage has not proven effective in managing these conditions, in part, because patients with heterogeneous kidney disease and hypertension etiologies are frequently grouped according to functional or severity classifications. Genetic testing may serve as an important tool in the armamentarium of clinicians who embrace precision medicine. Increasing scientific evidence has supported the utilization of genomic information to select efficacious antihypertensive therapy and understand hereditary contributors to chronic kidney disease progression. Given the wide array of antihypertensive agents available and diversity of genetic renal disease predictors, a panel-based approach to genotyping may be an efficient and economic means of establishing an individualized blood pressure response profile for patients with various forms of chronic kidney disease and hypertension. In this manuscript, we discuss the validation process of a Clinical Laboratory Improvement Amendments-approved genetic test to relay information on 72 genetic variants associated with kidney disease progression and hypertension therapy. These genomic-based interventions, in addition to routine clinical data, may help inform physicians to provide personalized therapy.

AB - Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates hypertension. A generalized approach to drug selection and dosage has not proven effective in managing these conditions, in part, because patients with heterogeneous kidney disease and hypertension etiologies are frequently grouped according to functional or severity classifications. Genetic testing may serve as an important tool in the armamentarium of clinicians who embrace precision medicine. Increasing scientific evidence has supported the utilization of genomic information to select efficacious antihypertensive therapy and understand hereditary contributors to chronic kidney disease progression. Given the wide array of antihypertensive agents available and diversity of genetic renal disease predictors, a panel-based approach to genotyping may be an efficient and economic means of establishing an individualized blood pressure response profile for patients with various forms of chronic kidney disease and hypertension. In this manuscript, we discuss the validation process of a Clinical Laboratory Improvement Amendments-approved genetic test to relay information on 72 genetic variants associated with kidney disease progression and hypertension therapy. These genomic-based interventions, in addition to routine clinical data, may help inform physicians to provide personalized therapy.

KW - chronic kidney disease

KW - hypertension

KW - implementation

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85058509933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058509933&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000361

DO - 10.1097/FPC.0000000000000361

M3 - Article

C2 - 30489456

AN - SCOPUS:85058509933

VL - 29

SP - 18

EP - 22

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 1

ER -